ACTUATE THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ELRAGLUSIB FOR TREATMENT OF PANCREATIC CANCER
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for elraglusib for treatment of patients with pancreatic cancer. Elraglusib (9-ING-41) is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is […]